[EN] HEMI-SYNTHETIC TRILOBINE ANALOGS FOR USE AS A DRUG<br/>[FR] ANALOGUES DE TRILOBINE SEMI-SYNTHÉTIQUES DESTINÉS À ÊTRE UTILISÉS COMME MÉDICAMENT
申请人:PF MEDICAMENT
公开号:WO2017055633A1
公开(公告)日:2017-04-06
The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
TRILOBINE DERIVATIVES AND THEIR USE THEREOF IN THE TREATMENT OF MALARIA
申请人:Institut Pasteur
公开号:EP3907227A1
公开(公告)日:2021-11-10
The present invention is in the field of therapeutic drugs to treat malaria. In particular, the invention provides trilobine derivatives per se, and trilobine derivatives for use in the treatment of malaria, for example drug-resistant malaria.
Anti-inflammatory effects of the partially purified extract of radix stephaniae tetrandrae
申请人:TCM Biotech International CORP.
公开号:US20040105907A1
公开(公告)日:2004-06-03
This invention relates to inflammatory responses in isolated peripheral human neutrophils that studied in the presence or absence of specially processed
Radix Stephaniae tetrandrae
(SPRST). We conclude that SPRST exerts anti-inflammatory effects by interfering with reactive oxygen species (ROS) production and calcium (Ca
2+
) influx through G-protein modulation to prevent Mac-1 up-regulation and firm adhesion by neutrophils during activation.Thns, SPRST may be clinical beneficial in the prevention of cardiovascular disease, or other diseases related to over activation of neutrophil.
Hemi-synthetic trilobine analogs for use as a drug
申请人:PIERRE FABRE MEDICAMENT
公开号:US10544156B2
公开(公告)日:2020-01-28
The invention concerns a compound of the following formula (I) or a pharmaceutically acceptable salt or solvate thereof as well as a pharmaceutical composition containing such a compound, and the use of such a compound as a drug, notably as a DNMT inhibitor, in particular in the treatment of cancer.
A topical composition comprising a lipoic acid, a carnitine, and a carnosine in a suitable vehicle for topical application and a method for treating skin is provided. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles and loss of elasticity. Preferred components include R-lipoic acid or R-dihydrolipoic acid, acetyl-1-carnitine, and 1-carnosine.